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Abstract: Depression and suicidal behavior have recently been shown to be associated with 
disturbances in structural and synaptic plasticity. Brain-derived neurotrophic factor (BDNF), 
one of the major neurotrophic factors, plays an important role in the maintenance and survival 
of neurons and in synaptic plasticity. Several lines of evidence suggest that BDNF is involved 
in depression, such that the expression of BDNF is decreased in depressed patients. In addi-
tion, antidepressants up-regulate the expression of BDNF. This has led to the proposal of 
the “neurotrophin hypothesis of depression”. Increasing evidence demonstrates that suicidal 
behavior is also associated with lower expression of BDNF, which may be independent from 
depression. Recent genetic studies also support a link of BDNF to depression/suicidal behavior. 
Not only BDNF, but abnormalities in its cognate receptor tropomycin receptor kinase B (TrkB) 
and its splice variant (TrkB.T1) have also been reported in depressed/suicidal patients. It has 
been suggested that epigenetic modulation of the Bdnf and Trkb genes may contribute to their 
altered expression and functioning. More recently, impairment in the functioning of pan75 
neurotrophin receptor has been reported in suicide brain specimens. pan75 neurotrophin receptor 
is a low-affinity neurotrophin receptor that, when expressed in conjunction with low availability 
of neurotropins/Trks, induces apoptosis. Overall, these studies suggest the possibility that BDNF 
and its mediated signaling may participate in the pathophysiology of depression and suicidal 
behavior. This review focuses on the critical evidence demonstrating the involvement of BDNF 
in depression and suicide.
Keywords: BDNF, neurotrophins, p75NTR, Trk receptor, depression, antidepressants, suicide, 
genetics, epigenetics
Introduction
Depression and suicide are important public health concerns. Depression affects about 
15% of the population at some point in their lives and is the leading cause of disability 
worldwide.1 About 9 million people are diagnosed as having depression each year in 
the United States alone, and the lost productivity and treatment expenses burden the 
US economy by more than US$43 billion per year.2,3 Depression is associated with an 
increased number of suicide attempts and increased lethality4,5 Suicide accounts for 
almost 2% of the world’s deaths.6 In most of the developed world, suicide is among the 
top 10 leading causes of death for individuals of all ages, and is the third leading cause 
of death among adolescents, after motor vehicle accidents and homicide.7–9 Several 
arguments suggest that suicidal behavior is a disorder of its own, although psychiatric 
disturbances, including depression, are major contributing factors.9,10 Autopsy studies 
of suicide victims have identified a high rate of major depressive disorder (MDD) Neuropsychiatric Disease and Treatment 2009:5 434
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as one of the main causes of increased mortality among 
suicide victims.11 The presence of psychopathology is a 
strong predictor; however, only a minority of people with 
such diagnoses commits suicide, which indicates that there 
is a certain predisposition to suicide that is independent of 
the main psychiatric disorders.9,12–14 Despite the devastating 
impact of depression and suicide on numerous lives, there 
is still a dearth of knowledge concerning the mechanisms 
underlying their pathogenesis.
Overwhelming evidence points to altered synaptic and 
structural plasticity in patients with depression and in suicidal 
patients. In fact, it has been proposed that depression/suicide 
results from an inability of the brain to make appropriate 
adaptive responses to environmental stimuli as a result of 
impaired synaptic plasticity and structural plasticity15–18 
Support for this comes from a variety of studies in major 
depressed/suicidal subjects demonstrating altered brain 
structure, such as reduction in cell number, density, cell 
body size, neuronal and glial density in frontal cortical or 
hippocampal brain areas and decrease in parahippocampal 
cortex cortical/laminar thickness.19–27 In addition, changes 
in synaptic circuitry,28 decreased dorsolateral prefron-
tal cortical activity,29,30 impaired synaptic connectivity 
between the frontal lobe and other brain regions,31,32 changes 
in the number and shape of dendritic spines,33,34 changes in 
the primary location of synapse formation, altered dendritic 
morphology of neurons in the hippocampus, decrease in 
length and number of apical dendrites,35 neuronal atrophy 
and decreased volume of the hippocampus,36–38 decreased 
number of neurons and glia in cortical areas,39 and spatial 
cognition deficits40 have also been reported during stress and 
depression. Furthermore, depression is associated with nega-
tive impact on learning and memory;41–43 and stress, a major 
factor in depression and suicide, hinders performances on 
hippocampal-dependent memory tasks and impairs induction 
of hippocampal long-term potentiation. These studies clearly 
demonstrate impaired structural and functional plasticity in 
depression and suicide; however, the precise molecular and 
cellular nature of events that lead to such altered plasticity 
in these disorders remains unclear.
Survival and development of neurons in the central 
nervous system (CNS) depends on the influence of a variety 
of extracellular signals. One set of signals is provided by 
neurotrophins. The role of neurotrophins in directing brain 
growth and neuronal functioning is being increasingly 
recognized. Neurotrophins not only play an important 
role in cellular proliferation, migration, and phenotypic 
differentiation and/or maintenance in the developing 
CNS,44,45 but their presence is required in the adult CNS 
for maintenance of neuronal functions, structural integrity 
of neurons, and neurogenesis46,47 which suggests that 
neurotrophins are biologically significant over the entire life 
span. In addition, a number of studies have demonstrated 
that neurotrophic factors regulate structural, synaptic, and 
morphological plasticity to modulate the strength or number 
of synaptic connections and neurotransmission.48,49 Thus, 
a pathological alteration of the neurotrophic factor system 
may not only lead to defects in neural maintenance and 
regeneration and, therefore, structural abnormalities in the 
brain, but may also reduce neural plasticity and, therefore, 
impair the individual’s ability to adapt to crisis situations.
Mammalian neurotrophins are homodimeric proteins that 
include nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), neurotrophin (NT) 3, and NT 4/5. Most 
functions of neurotrophins are mediated by the tropomycin 
receptor kinase (Trk) family of tyrosine kinase receptors. 
The interaction of neurotrophins with the Trk receptors is 
specific: NGF binds with TrkA, BDNF and NT 4 both bind 
with TrkB, and NT 3 binds with the highest affinity to TrkC 
but is also capable of signaling through TrkA and TrkB. 
In addition to the full length TrkB receptor, several non-
catalytic truncated TrkB isoforms have also been identified; 
these isoforms lack the signaling domain, preventing the 
induction of a signal transduction mechanism. Binding of 
a neurotrophin to the appropriate Trk receptor leads to the 
dimerization and transphosphorylation of tyrosine residues 
in the intracellular domain of the Trk receptors and subse-
quent activation of cytoplasmic signaling pathways.50,51 All 
neurotrophins can bind to the pan75 neurotrophin receptor 
(p75NTR), which plays a role in neurotrophin transport, ligand 
binding specificity, and Trk functioning.44,52,53
Of various neurotrophins, BDNF has attracted a great 
deal of interest as a functional candidate gene in various 
mental disorders. The Bdnf gene lies on the reverse strand 
of chromosome 11p13 and encodes a precursor peptide 
pro-BDNF.54 In fact, all neurotrophins, including BDNF, 
are synthesized as a pre-pro-neurotrophin precursor that 
undergo posttranslational modifications before giving rise 
to mature homodimeric protein. The pro-BDNF is produced 
in endoplasmic reticulum, which is accumulated in trans-
Golgi network via Golgi apparatus. It has been suggested 
that pro-BDNF binds to sortilin in the Golgi, which facilitates 
the correct folding of the mature domain. The mature domain 
of BDNF binds to carboxypeptidase E, thereby sorting 
BDNF to the regulated secretary pathway.55 A substitu-
tion of valine (Val) to methionine (Met) at codon 66 in the Neuropsychiatric Disease and Treatment 2009:5 435
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prodomain impairs this sorting of BDNF.56 The pro-BDNF 
is the main form of neurotrophin,57–59 and the mature form 
originates through proteolytic cleaving. Plasmin is the 
major extracellular protease that cleaves pro-BDNF.60,61 The 
expression of the BDNF gene is tightly regulated by neuronal 
activity, through mechanisms dependent on calcium.62 
In addition to BDNF, the function of a receptor for BDNF 
(ie, TrkB) is also regulated in an activity-dependent manner. 
TrkB is primarily localized in the synaptic sites. Further local-
ization of TrkB occurs at the synaptic sites after neuroanal 
activity.55 Neuronal activity, therefore, is critical for synthesis 
and intracellular targeting of TrkB receptors.55 Thus, BDNF 
release and expression of TrkB receptors in a coordinated 
fashion are important for optimal synaptic response.
The role of BDNF in depression has gained broad 
attention because many pre-clinical and clinical studies 
provide direct evidence suggesting that modulation in 
expression of BDNF could be involved in behavioral phe-
nomenon associated with depression. Based on these studies, 
the neurotrophin hypothesis of depression was proposed, 
which suggests that stress and depression is associated with 
decreased expression of BDNF and that antidepressants 
alleviate depressive behavior by increasing its level.15,16 This 
is quite relevant given that BDNF is involved in synaptic 
plasticity and, as earlier mentioned, compromised synaptic 
and structural plasticity have been shown to be associated 
with depression. Because stress and depression are the major 
contributory factors in suicide, recently, a number of studies 
have attempted to investigate the role of BDNF in suicidal 
behavior. These studies, albeit in infancy, provide strong 
support for the idea that abnormalities in BDNF could be 
an important contributory factor in suicidal behavior. This 
review focuses on the critical assessment of the involvement 
of BDNF and its functioning in depression and suicidal 
behavior.
BDNF in stress
Several clinical and epidemiological studies have identified 
stressors as important risk factors in depression and suicide.63–70 
An overactive hypothalamus-pituitary-adrenal axis has been 
well established in stress. On the other hand, there is strong 
evidence for a connection between stress system overactiv-
ity and suicidal behavior. For example, in suicide victims, 
hypothalamus-pituitary-adrenal axis hyperactivity has been 
linked with elevated corticotrophin-releasing hormone 
levels in the cerebrospinal fluid, reduced corticotrophin-
releasing hormone binding sites in the frontal cortex, 
augmented pro-opiate-melanocortic RNA density in the 
pituitary, large corticotrophic cell size, and alterations in the 
mineralocorticoid to glucocorticoid receptor messenger RNA 
(mRNA) ratio in the hippocampus of suicide victims.71–76 
Also, a consistent association has been found between 
subsequently completed suicide and nonsuppression of 
cortisol in the dexamethasone suppression test.77–82
Studies in pre-clinical models have shown stress-induced 
dysregulation of BDNF expression. Several types of stressors 
have been used to examine the role of BDNF in stress-related 
disorders. The very first study that examined the role of 
stress was from Smith and colleagues,83 who demonstrated 
that immobilization stress used for 1 or 7 days (for 2 hours 
per day) significantly decreased BDNF mRNA expression 
in the hippocampus. This decrease was present throughout 
the hippocampus; however, the dentate gyrus showed the 
most significant response. This was later confirmed by other 
investigators.84,85 Similar changes were observed when other 
types of stressors were used. For example, Rasmusson et al86 
demonstrated that exposure to twenty 0.5-second 0.4-mA foot 
shocks coterminating with 70-dB, 5-second-long pure tones 
over 60 minutes decreased dentate gyrus BDNF mRNA. 
Some of the stressors, such as social defeat, decreased BDNF 
not only in hippocampus but also in cortical and subcortical 
areas of mice.87 Interestingly, it has been shown that maternal 
separation led to depression like behavior in adulthood, which 
was correlated with decreased BDNF expression.88 This study 
suggests that early developmental insult causes depression 
in later life, which is mediated through abnormalities in 
BDNF-mediated signaling.
Several studies have shown that exposure of exogenous 
corticosterone (to mimic the stress effect) also reduces BDNF 
expression in rodent hippocampus, similar to that observed 
in various pre-clinical stress models.83,89–91 Recently, we 
examined the effects of corticosterone treatment on BDNF 
expression in detail and found that the mRNA level of 
BDNF was not only decreased in the hippocampus but that 
the frontal cortex also showed significantly reduced expres-
sion of BDNF.92 This suggests that the effects of glucocor-
ticoids on BDNF are not limited to the hippocampus; other 
brain areas are also equally affected. When endogenous 
corticosterone was removed by adrenalectomy, the level 
of BDNF in the hippocampus increased.89,93 On the other 
hand, dexamethasone replacement to adrenalectomized rats 
restored the level of BDNF to control levels.93 These studies 
demonstrate that expression of BDNF expression is regulated 
via glucocorticoids.
On a molecular level, BDNF is highly regulated. The 
rat Bdnf gene contains 4 separate promoters that are linked Neuropsychiatric Disease and Treatment 2009:5 436
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to 4 main transcript forms.94,95 Each transcript has 4 short 
5’ noncoding exons (I-IV) containing separate promoters 
and 1 shared 3’ exon (exon V) encoding the mature BDNF 
protein. Although the biological significance of these BDNF 
transcripts is not clear, it appears that these transcripts can 
facilitate multi-level regulation of BDNF expression and 
may determine the tissue-specific expression. To examine 
the molecular basis of stress regulation of  BDNF, we deter-
mined mRNA levels of exons I through IV. We observed 
that corticosterone selectively decreased the expression of 
transcripts II and IV, but not transcripts I or III, in both the 
frontal cortex and hippocampus.92 Two other recent studies 
suggest that immobilization stress decreases total BDNF 
expression, along with a specific decrease in exon IV in the 
hippocampus96 and hypothalamus.97 These studies suggest 
that the decrease of BDNF mRNA expression by glucocorti-
coids may be due to a decrease in expression of the specific 
BDNF transcripts that contain exons II and IV.
BDNF in depression
In addition to stress, several lines of evidence point to 
the involvement of BDNF in depression. These include 
indirect evidence demonstrating that antidepressants regu-
late BDNF/TrkB expression and that BDNF itself shows 
antidepressant-like effects. In addition, depressed patients 
show alterations in expression of BDNF both in blood cells 
and in postmortem brain tissues. Genetic studies also link 
BDNF polymorphism to depression. Each of these aspects 
are detailed further.
regulation of BDNF expression  
by antidepressants
The effects of antidepressants on the expression of the Bdnf 
gene have been investigated extensively. In general, it has 
been shown that when given to healthy rodents, several 
classes of antidepressants, including monoamine oxidase 
inhibitors, selective serotonin reuptake inhibitors, tricyclic 
agents, noradrenaline reuptake inhibitors, and noradrenergic 
and specific serotonergic antidepressants, all increase expres-
sion of BDNF in the brain.98–108 In addition, several other 
agents known to have antidepressant properties also increase 
expression of BDNF in rodent brain. These agents include 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
and N-methyl-D-aspartate antagonists, electroconvulsive 
shock, and transcranial magnetic stimulation.98,109–114 Chronic 
treatment with antidepressants not only increases expres-
sion of BDNF in healthy rodents, but also reverses down-
regulation of BDNF caused by stress.98,115,116 However, these 
effects depend on various factors, including length of 
administration, class of antidepressant, route of administra-
tion, age of animal, and doses of the drugs. In general, an 
increase in BDNF expression occurs only after long-term 
treatment and, in most cases, short-term treatment with 
antidepressants causes no change in the expression of 
BDNF.98,101,106,117,118 However, short-term treatment with 
antidepressants has also been shown to cause an increase in 
BDNF expression in the cortex119,120 and even a decrease in 
the hippocampus.101,119,120
The effects of antidepressants such as desipramine or 
fluoxetine have also been studied in BDNF-deficient mice. 
These studies show that the behavioral effects of antidepres-
sant are abolished in BDNF-deficient mice,121,122 suggesting 
that BDNF plays an important role in the behavioral effects 
of antidepressants.
regulation of BDNF exons  
by antidepressants
To examine how BDNF is regulated in response to 
antidepressants, we administered different classes of 
antidepressants (serotonin uptake blocker, fluoxetine, 
norepinephrine blocker, desipramine, monoamine oxidase 
inhibitor, or phenelzine) to healthy rats and examined 
whether antidepressants regulate the expression of BDNF 
via specific BDNF transcript(s).92 We observed very 
interesting results such that treatment of healthy rats with 
desipramine or phenelzine increased mRNA levels of total 
BDNF in both the frontal cortex and hippocampus, whereas 
fluoxetine increased the mRNA level of BDNF only in the 
hippocampus.92 More interestingly, when we examined the 
effects of antidepressants on the expression of individual 
exons containing BDNF transcripts, we found that desipra-
mine specifically increased exons I and III in both the frontal 
cortex and hippocampus; fluoxetine increased only exon II 
in the hippocampus; and phenelzine effectively increased 
exons I and IV in the hippocampus but only exon I in the fron-
tal cortex. In another study, Dias et al102 examined the effects 
of long-term antidepressants on BDNF transcript levels in 
the rat hippocampus, amygdala, and cortex. They observed 
that desipramine increased exon III in different cortical areas, 
whereas fluoxetine had no significant effects on BDNF exons 
in any of the brain areas studied. Another recent study by 
Altieri et al118 also showed no effect of long-term fluoxetine 
treatment on BDNF transcripts in the hippocampus. Our 
observation of increased exon III by desipramine is similar 
to the findings of Dias et al102 but we also noted an increase 
in the expression of exon I. In addition, contrary to reports Neuropsychiatric Disease and Treatment 2009:5 437
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by Dais et al102 and Altieri et al118 we found a selective 
increase in exon II by fluoxetine in both the frontal cortex 
and hippocampus. Although some of these discrepancies can 
be attributed to route of administration or doses of drugs, 
these findings suggest that there is no unified mechanism for 
the regulation of BDNF exon(s) by antidepressants and that 
various classes of antidepressants may affect BDNF exon 
expression differently.
We further examined whether antidepressants reverse 
the corticosterone-mediated decrease in BDNF and whether 
similar BDNF exons are involved in this mechanism by which 
antidepressants upregulate BDNF expression.92 We observed 
that long-term treatment with desipramine completely 
reversed the corticosterone-induced decrease in BDNF in 
both the frontal cortex and hippocampus. Fluoxetine was able 
to partially reverse the changes in hippocampal BDNF, but 
did not cause any change in the frontal cortex. Phenelzine, on 
the other hand, reversed the corticosterone-induced decrease 
in BDNF partially in the frontal cortex and completely in the 
hippocampus. Interesting results were noted when individual 
BDNF transcripts were examined after antidepressant treat-
ment of corticosterone-implanted rats: the antidepressants 
were able to increase mRNA levels of only those BDNF 
transcripts that were affected when the respective antidepres-
sant was given to healthy rats without corticosterone pellet 
implantation. Thus, desipramine increased exons I and III 
in the frontal cortex and hippocampus, fluoxetine increased 
exon II in the hippocampus, and phenelzine increased exon I 
in the frontal cortex and exons I and IV in the hippocampus. 
Surprisingly, except for the changes in exon II by fluoxetine 
in the frontal cortex and in exon IV by phenelzine in the hip-
pocampus, the corticosterone-mediated decrease in exons II 
and IV persisted even after antidepressant treatment. How-
ever, the overall observation was that all the antidepressants 
increased the level of total BDNF mRNA in the brain of 
corticosterone-treated rats. Although it is difficult to assess 
the extent of involvement of a particular exon in regulation 
of overall BDNF expression, there is complete reversal by 
desipramine in both the frontal cortex and hippocampus 
because the increase in exon III was very robust in these brain 
areas. On the other hand, in the hippocampus, fluoxetine was 
able to reverse the corticosterone-mediated decrease of only 
exon II, but not exon IV; therefore, the reversal was partial. 
However, no effect of fluoxetine on total BDNF expression 
was observed in the frontal cortex, because fluoxetine was 
not able to increase either exon II or IV in the frontal cortex. 
On the other hand, phenelzine was partially effective in the 
frontal cortex because of its effects on exon II, but complete 
reversal was noted in the hippocampus because phenel-
zine increased the levels of both corticosterone-decreased 
exons II and IV. Thus, it appears that antidepressants are 
effective in causing an increase in total BDNF expression 
in corticosterone-treated rats; however, the mechanisms for 
the down-regulation of BDNF transcripts by corticosterone 
and those that affect their upregulation by antidepressants 
are quite different.
TrkB studies in relation  
to antidepressant treatment
In addition to BDNF, TrkB receptors have also been studied 
in relation to antidepressant treatment. The Trkb gene can 
give rise to at least 2 isoforms of TrkB, encoding the “full-
length,” or catalytic, form of TrkB, the receptor mediating the 
main biological actions of BDNF,123,124 and the “truncated” 
TrkB receptors (TrkB.T1), which lack a large part of the 
intracellular domain and do not display protein–tyrosine 
kinase activity.125 Binding with BDNF leads to activation of 
the full-length TrkB receptors by ligand-induced dimerization 
and autophosphorylation of tyrosine residues in the intracel-
lular region.126 Full-length TrkB receptors also mediate retro-
grade transport of BDNF to neuronal cells.127 The activated 
receptors become able to interact and phosphorylate several 
intracellular targets. Although catalytic TrkB is considered 
as the receptor mediator of the main biological actions of 
BDNF, the truncated TrkB is also a predominant isoform 
in the adult brain,128,129 functioning as a cellular adhesion 
molecule regulating synaptic plasticity and axonal outgrowth, 
modulating signaling by catalytic TrkB through the formation 
of heterodimers, and regulating the extracellular availability 
of its endogenous ligands.125 It has been shown that BDNF 
signaling is impaired as a consequence of the formation of 
receptor heterodimers,130 which suggests that the truncated 
form of TrkB can act as a negative modulator of BDNF 
signaling.
It has been shown that long-term treatment with electro-
convulsive shock, desipramine, fluoxetine, tranylcypromine, 
and sertraline all increased mRNA levels of TrkB in the rat 
brain.98 Recently, Rantamäki et al131,132 reported that not only 
the expression, but TrkB signaling, is rapidly activated by a 
variety of antidepressants in mouse medial prefrontal cortex 
(PFC) and hippocampus. This occurs through antidepressant-
mediated autophosphorylation of TrkB. These studies sug-
gest that the behavioral effect of antidepressants requires 
TrkB activation along with an increase in BDNF expression. 
Interestingly, the TrkB-mutant mice do not exhibit 
depression-like behaviors such as increased “despair” in Neuropsychiatric Disease and Treatment 2009:5 438
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the forced swim test.133 However, TrkB.T1-overexpressing 
transgenic mice, which show reduced TrkB activation in 
the brain, and heterozygous BDNF null (BDNF+/-) mice 
both are resistant to the effects of antidepressants in the 
forced swim test, indicating that normal TrkB signaling is 
required for the behavioral effects typically produced by 
antidepressants.121
Antidepressant-like effect of BDNF
The role of BDNF in depression also stems from preclinical 
studies demonstrating that BDNF not only regulates expres-
sion of  BDNF but shows antidepressant-like effects in animal 
models. In a learned helplessness model of depression, 
infusion of BDNF reduces escape latencies and failure rates 
in rodents,134,135 suggesting the effectiveness of BDNF in 
reducing inescapable random shock-induced depressive 
behavior. Similarly, intra-midbrain infusion of BDNF in 
rodents produces antidepressant-like effect in the forced 
swim test and learned helpless models of depression.134 
Infusion of BDNF in the dorsal raphe nucleus also resulted 
in antidepressant-like effect in the learned helpless model 
of depression.136 Interestingly, the effects of BDNF on these 
behavioral paradigms were much longer lasting compared 
with classic antidepressants.135,137
Clinical studies of BDNF response  
in depressed patients before  
and after antidepressant treatment
Consistent with animal studies, studies in humans provide 
evidence that BDNF plays an important role in depression. 
Although BDNF is highly expressed in the brain, studies 
regarding the expression level of BDNF in the human brain 
of depressed subjects are limited. In an earlier study, Chen 
et al138 showed that the expression of BDNF is increased 
in the postmortem brain of depressed subjects treated with 
antidepressants compared with those who were untreated. 
Recently, many studies have attempted to examine the level 
of BDNF in serum or platelets of depressed subjects with and 
without antidepressant treatment. Although the significance of 
measurement of BDNF in blood cells is unclear, it was demon-
strated that BDNF may cross the blood-brain barrier and that 
platelet BDNF shows similar changes postnately similar to the 
brain,139 suggesting that there are parallel changes in the blood 
and brain levels of BDNF. Karege and colleagues140 were the 
first to compare BDNF levels in the serum of depressed sub-
jects and healthy controls. In 15 male and 15 female depressed 
patients, they found that BDNF level was significantly lower 
compared with healthy controls. This decrease was negatively 
correlated with the severity of depression. Moreover, they 
found a sex effect such that female depressed patients were 
more severely depressed and released less BDNF than males. 
Recently, the same group of investigators suggested that the 
decrease in serum BDNF in depressed patients is related to 
release mechanisms of BDNF because no change was found 
in the level of BDNF in blood, but serum and platelet BDNF 
were decreased in depressed patients.141 Since then, several 
studies have examined BDNF level in these peripheral tissues 
before and after antidepressant treatment. For example, Gonul 
et al142 and Piccinni et al143 reported decreases in serum BDNF 
level in depressed patients. On the other hand, Matrisciano 
et al144 examined serum BDNF levels in healthy subjects and 
depressed patients at baseline and after 5 weeks and 6 months 
of sertraline, escitalopram, or venalfaxine treatment. They 
found that the BDNF level was lower in depressed patients 
and that sertraline increased BDNF level after 5 weeks and 
6 months, whereas escitalopram increased BDNF level only 
after 6 months. Venalfaxine did not change the level of 
BDNF. There was a negative correlation between increase 
in BDNF level and decrease in Hamilton Depression Rating 
Scale score. On the other hand, Gonul et al142 reported that 
depressed patients show increased BDNF level in serum 
after treatment with a variety of antidepressants for 8 weeks, 
including venalfaxine, sertraline, fluoxetine, paroxetine, and 
citalopram. Similarly, increases in serum BDNF level by 
amitriptyline after 36 days, paroxetine after 4 or 8 weeks, or 
venalfaxine after 12 weeks of treatment to depressed patients 
were reported.145–147 Not only antidepressants but vagus nerve 
stimulation, repetitive transcranial magnetic stimulation,148 
or electroconvulsive therapy149 to depressed patients also 
cause an increase in serum BDNF level in depressed patients. 
In a recent meta-analysis, Brunoni et al150 and Sen et al151 
concluded that BDNF levels are lower in depressed patients 
than healthy controls and that BDNF levels are significantly 
higher after antidepressant treatment. Overall, these findings 
provide strong evidence of modulation in BDNF in depression 
and in response to antidepressants.
role of BDNF in genetic basis  
of depression
The gene encoding human BDNF is localized at chromosome 
11p13. In humans, a common single nucleotide polymorphism 
at nucleotide 196 within the 5’ pro-BDNF sequence encodes 
a variant BDNF at codon 66 (Val66-Met). As mentioned 
earlier, this Met66 variant affects activity-dependent BDNF 
secretion.56,59 This is critical for dendritic trafficking and 
synaptic localization of BDNF. Interestingly, knockout Neuropsychiatric Disease and Treatment 2009:5 439
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mice carrying the Val66Met polymorphism show reduced 
activity-dependent secretion of BDNF, without any change in 
the level of total BDNF.152 More interestingly, mice carrying 
the BDNF Met/Met or Val/Met allele show a reduced volume 
of hippocampus compared with wild-type mice, and BDNF 
Met/Met knock-in mice have reduced dendritic arbor com-
plexity.152 These studies are quite relevant to depression, 
because structural abnormalities, particularly structural 
abnormalities in the brain, including reduced hippocampal 
volume during stress and in depressed patients, have been 
reported,153,154 which increases the risk for depression. 
Recently, Frodl et al155 examined the effect of the BDNF 
Val66Met polymorphism on hippocampal and amygdala 
volumes in patients with depression and in healthy control 
subjects. They found that depressed patients had significantly 
reduced hippocampal volumes. They also found smaller 
hippocampal volumes for depressed patients and for healthy 
controls carrying the Met-BDNF allele when compared with 
subjects homozygous for the Val-BDNF allele. No significant 
difference in amygdala volume was found between depressed 
patients and healthy controls and no significant main effects 
for the BDNF Val66Met polymorphism were observed. They 
concluded that the Met-BDNF allele carriers might be at risk 
of developing smaller hippocampal volumes and might be 
susceptible to depression. Interestingly, human magnetic 
resonance imaging studies in normal healthy subjects showed 
that Val/Val homozygotes had a larger hippocampal volume 
than Val/Met heterozygotes.156–158
People with the Met allele also have poor hippocampal-
dependent memory function and hippocampal hyperac-
tivation during learning,56,159 which could be associated 
with hippocampal hypersensitivity to stress. On the other 
hand, Kliem et al160 demonstrated that training-dependent 
increases in the amplitude of motor-evoked potentials and 
motor map reorganization are reduced in healthy subjects 
with a Val66Met polymorphism in the Bdnf gene, compared 
with subjects without the polymorphism. These results sug-
gest that BDNF is involved in mediating the experience-
dependent plasticity of the human motor cortex. Furthermore, 
the Val66Met polymorphism in the Bdnf gene modulates 
human cortical plasticity and the response to transcranial 
magnetic stimulation.161
Earlier, Tsai et al162 studied the Bdnf gene Val66Met 
polymorphism in 152 patients with MDD and in 255 healthy 
controls. They also examined the association of this 
polymorphism and fluoxetine therapeutic response in 
110 patients with MDD who received a 4-week fluoxetine 
treatment. They found no significant differences for the 
genotype or allele frequency of the BDNF polymorphism 
comparing the MDD and control groups. Further, no 
significant differences were noted comparing the 3 genotype 
groups for depressive-cluster symptoms. However, a trend 
to improved 4-week fluoxetine antidepressant response 
was demonstrated for heterozygous patients compared with 
homozygous analogs. Similarly, Choi et al163 reported that 
the genotype, allele, and allele-carrier distributions for the 
Val66Met polymorphism did not differ significantly between 
patients with MDD and healthy controls; however, they 
showed that the Val66Met polymorphism of BDNF was 
associated with citalopram efficacy, with Met-allele carriers 
responding better to citalopram treatment.
Very recently, Licinio et al164 studied novel genetic 
polymorphisms in the BDNF gene and assessed their 
frequencies and associations with MDD or antidepressant 
response. They identified 83 novel single-nucleotide poly-
morphisms (SNPs): 30 in untranslated regions, 4 in coding 
sequences, 37 in introns, and 12 in upstream regions; 3 of 
4 rare novel coding SNPs were nonsynonymous. Association 
analyses of patients with MDD and controls showed that 
6 SNPs were associated with MDD (rs12273539, rs11030103, 
rs6265, rs28722151, rs41282918, and rs11030101) and 
2 haplotypes in different blocks (one including Val66, 
another near exon VIIIh) were significantly associated with 
MDD. One recently reported 5’ untranslated region SNP, 
rs61888800, was associated with antidepressant response.
Hwang et al165 reported that the BDNF Val66Met 
genotype distribution was significantly different between 
geriatric depressed patients and healthy subjects and there 
was a significant excess of the Met allele in these patients 
compared with the control group. Very recently, Duncan 
et al166 found that the Val/Val genotype was associated 
with higher scores on the Cognitive-Affective factor of the 
Beck Depression Inventory-II, Cognitive-Affective factor 
scores, and Somatic-Vegetative factor scores, suggesting an 
association between the Val/Val genotype and higher levels 
of depression symptoms. In a similar line of investigation, 
Savitz et al167 showed that bipolar patients, who were metal-
lele carriers, and were exposed to sexual abuse, performed 
more poorly on memory test, suggesting that functional 
BDNF polymorphism and cognition would moderate the 
effect of psychological trauma on memory. Similar findings 
were later reported by other investigators.168,169 Interestingly, 
Childhood adversity per se predict higher levels of adult 
depressive symptoms and BDNF Val66Met polymorphisms 
moderate the effect of childhood sexual abuse on adult 
depressive symptoms.170Neuropsychiatric Disease and Treatment 2009:5 440
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behavior is associated with alterations in BDNF and its 
cognate receptors. It is more interesting to examine whether 
alterations in BDNF in suicidal subjects are independent of 
depression. In this regard, postmortem brain studies in suicide 
subjects with or without depression, levels of BDNF in blood 
cells of suicidal patients, and genetic association studies 
linking BDNF to suicide have been performed. These studies 
indicate a possible role of BDNF to suicidal behavior.
Human postmortem brain studies
To my knowledge, we were the first to examine of the role of 
BDNF in suicide. We determined mRNA and protein expression 
of BDNF in the PFC (Brodmann’s area 9) and hippocampus 
from specimens obtained from 21 fully characterized suicide 
subjects and 27 nonpsychiatric healthy control subjects.181 We 
observed that mRNA level of BDNF was significantly reduced, 
independently and as a ratio to neuron-specific enolase 
(a housekeeping gene), in both the PFC and hippocampus of 
suicide subjects compared with nonpsychiatric healthy control 
subjects. These reductions were associated with a significant 
decrease in the protein level of BDNF. Interestingly, when we 
divided suicide subjects into those who had depression and 
those who had another psychiatric disorder, we found that the 
decrease in expression of BDNF was present in all suicide 
subjects regardless of psychiatric diagnosis. Our findings 
demonstrate that suicidal behavior may be associated with a 
decrease in BDNF functioning. More recently, Karege et al182 
examined the expression of BDNF in the PFC, hippocampus, 
and entorhinal cortex in suicide subjects. Similar to our 
findings, they reported that the level of BDNF was significantly 
decreased in the PFC and hippocampus. No change was 
found in the entorhinal cortex, suggesting that a decrease in 
BDNF may be specific only to certain brain areas. In addition, 
Karege et al182 found that suicide subjects who were receiving 
antidepressant treatment did not show any change in the level 
of BDNF, suggesting that psychotropic drugs normalize the 
decreased level of BDNF in suicide subjects. Interestingly, 
Kozcicz et al183 reported sex-specific changes in the level 
of BDNF in suicide subjects. They found that BDNF level 
was much lower in the midbrain (nonpreganglionic Edinger-
Westphal nucleus) of male suicide subjects, whereas female 
suicide subjects showed an increased level of BDNF in this 
brain area, suggesting a possible sex effect in the regulation of 
BDNF expression in suicide subjects. Although the previous 
studies did not find sex-specific changes in BDNF expression 
in the hippocampus or cortical areasb,181,182 whether sex-
specific effect in BDNF expression is specific to the midbrain 
area needs further studies.
Another piece of evidence demonstrating role of BDNF 
in depression comes from studies showing an association 
of personality traits and BDNF polymorphism.171–174 It is 
pertinent to mention that personality traits have been linked 
to major depression as well as suicide.175
Do epigenetics play any role  
in BDNF modification in depression  
and antidepressant responses?
Recent studies suggest that epigenetic regulation of the gene 
may be crucial in the pathophysiology of depressive behavior.176 
Histone modifications along with DNA methylation play a 
major role in gene silencing through chromatin remodeling. 
Methyl-CpG binding protein MeCP2, which encodes a protein 
that functions as a transcriptional repressor, selectively binds 
to BDNF promoter III and represses expression of the Bdnf 
gene. Membrane depolarization triggers the calcium-dependent 
phosphorylation and release of MeCP2 from BDNF 
promoter III, thereby facilitating transcription.177 On the 
other hand, membrane depolarization causes increased BDNF 
transcription, which involves dissociation of the MeCP2-histone 
deacetylase-mSin3A repression complex from its promoter,177,178 
which suggests that DNA methylation-related chromatin remod-
eling is important for activity-dependent Bdnf gene regulation. 
Recently, Fuchikami et al179 reported that single immobilization 
stress (a model for depression) decreased the levels of BDNF 
mRNA, which was associated with decreased expression of 
exons I and IV. They also reported that the levels of acetylated 
histone H3 were decreased in the promoters of I, IV, and VI 
exons, suggesting that histone acetylation is involved in regula-
tion of the Bdnf gene in the immobilization stress model. Earlier, 
in an important study, Tsankova et al180 found that social defeat 
stress caused down-regulation of BDNF exons III and IV and 
robustly increased histone methylation at their corresponding 
promoters. Long-term imipramine treatment reversed this down-
regulation and increased histone acetylation at these promoters. 
This hyperacetylation by long-term imipramine treatment was 
associated with a selective down-regulation of histone deacety-
lase. Overexpression of HDAC5 blocked the ability to reverse 
depression-like behavior. Altogether, these studies suggest that 
although BDNF expression is repressed or induced by stress or 
antidepressants by different mechanisms, epigenetic regulation 
of the BDNF gene plays an important role in depression and in 
the mechanisms of action of antidepressants.
BDNF in suicide
Because depression is an important causative factor in suicidal 
behavior, it is interesting to examine whether suicidal Neuropsychiatric Disease and Treatment 2009:5 441
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In addition to adult suicide subjects, we recently 
examined the expression of BDNF in postmortem brain 
samples obtained from teenaged suicide subjects.184 Protein 
and mRNA expression of BDNF was determined in samples 
from the PFC, Brodmann’s area 9, and hippocampus 
obtained from 22 teenaged suicide victims and 22 matched 
nonpsychiatric healthy control subjects. As with adult 
suicide subjects, we found that protein expression of BDNF 
was significantly decreased in the PFC of teenaged suicide 
subjects. Interestingly, no significant change in BDNF pro-
tein expression was observed in the hippocampus. On the 
other hand, a decrease in BDNF mRNA was observed both 
in the PFC and hippocampus of teenaged suicide subjects. 
Whether this subtle difference in the protein expression 
of BDNF represents differences in some characteristics 
between teenage and adult suicide is not clear. Nonetheless, 
this study further suggests that BDNF is involved in suicidal 
behavior.
Blood cell studies
As in depressed patients, the BDNF level in blood cells has 
also been examined in patients with suicidal ideation or in 
those who have attempted suicide. Deveci et al185 investigated 
whether their serum BDNF levels differ among suicide 
attempters without a major psychiatric disorder compared 
with patients with MDD and healthy subjects. Ten suicide 
attempters, 24 patients with MDD, and 26 subjects without 
any psychiatric diagnosis and any psychiatric treatment were 
examined. They found that serum BDNF levels were lower 
in both the attempted suicide group and the MDD group vs 
the control group. In another study, Kim et al186 measured 
plasma BDNF levels in 32 depressed patients who had 
recently attempted suicide, 32 nonsuicidal depressed patients, 
and 30 healthy controls. They found that BDNF levels were 
significantly lower in suicidal depressed patients than non-
suicidal depressed patients or healthy controls. Interestingly, 
BDNF levels were not different between fatal and nonfatal 
suicide attempts. Similarly, Lee et al187 found that plasma 
BDNF level was decreased in depressed suicidal patients vs 
depressed nonsuicidal patients. These studies suggest that 
reduction of plasma BDNF level is related to suicidal behav-
ior in depression and that BDNF level may be a biological 
marker of suicidal depression. However, when BDNF level 
was determined in platelets, it was found that platelet BDNF 
levels were lower in both nonsuicidal and suicidal depressed 
patients compared with healthy controls, whereas no sig-
nificant differences were noted between nonsuicidal and 
suicidal depressed patients.188 Interestingly, Dawood et al189 
used direct internal jugular vein blood sampling methods to 
circumvent the issue of whether BDNF is released from other 
sources than the brain and they examined the relationship 
between brain BDNF production and suicide risk in untreated 
patients with depression. They used veno-arterial BDNF 
plasma concentration gradient as an index of brain BDNF 
production. Of the patients, 11 had low suicide risk and 8 
had a moderate to high suicide risk. The veno-arterial BDNF 
concentration gradient was significantly reduced in patients 
at medium to high suicide risk and there was a significant 
negative correlation between suicide risk and the internal 
jugular venous veno-arterial BDNF concentration gradient. 
This study suggests an association between internal jugular 
venous BDNF overflow and suicide risk.
Genetic studies linking BDNF to suicide
Hong and colleagues190 were the first to study an association 
of BDNF with suicide. They did not find any significant asso-
ciation of Val66Met polyorphism and suicidality in bipolar 
patients of Chinese origin. Recently, Kim et al191 examined 
BDNF Val/Met polymorphism in bipolar disorder in Korean 
subjects and whether clinical features vary according to geno-
type. They found that allelic distributions did not differ signif-
icantly between bipolar patients and healthy normal controls; 
however, the rate of suicide attempts among the Val/Val, 
Val/Met, and Met/Met genotype groups was significantly 
different. Relative to patients with the Val/Val genotype, 
those with the Met/Met genotype had a 4.9-fold higher 
risk of suicide attempts, suggesting that BDNF Val/Met is 
related to the suicidal behavior in bipolar patients. On the 
other hand, Sarchiapone et al192 genotyped 170 depressed 
patients for their history of suicide attempts and BDNF 
Val/Met polymorphism. Depressed patients who carried the 
BDNF Val/Met polymorphism variant (GA + AA) showed 
significantly increased risk of suicidal behavior. The risk of 
a suicide attempt was also significantly higher among those 
reporting higher levels of childhood emotional, physical, and 
sexual abuse. Secondary analyses suggested that depression 
severity was a significant risk factor only in the wild-type 
BDNF genotype, and that the risk of suicide attempts was 
more predictable within the wild-type group. The same group 
of investigators extended this study in postmortem samples 
of subjects who completed suicide and healthy controls.193 
They did not find a significant association of BDNF Val/Met 
polymorphism with suicide. They argued that even if family 
studies showed a shared inheritability of suicidal tendencies 
between suicide attempters and completers, completed sui-
cide and attempted suicide may have two distinct phenomena Neuropsychiatric Disease and Treatment 2009:5 442
Dwivedi Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and different molecular genetic components may be involved. 
They also analyzed two other polymorphisms in the Bdnf 
gene, -270C  T and -281C  A, and found their occur-
rence as less than 5%. Interestingly, Perroud et al194 examined 
whether a Val/Met BDNF polymorphism could moderate 
the effect of childhood maltreatment on the onset, number, 
and violence of suicidal behavior in suicide attempters. They 
reported that childhood sexual abuse was associated with 
violent suicide attempts in adulthood only among Val/Val 
individuals and not among Val/Met or Met/Met individuals. 
The severity of childhood maltreatment was significantly 
associated with a higher number of suicide attempts and 
with a younger age at onset of suicide attempt. This result 
suggests that Val/Met modulates the effect of childhood 
sexual abuse on the violence of suicidal behavior and that 
BDNF dysfunction may enhance the risk of violent suicidal 
behavior in adulthood. Altogether, these studies clearly link 
BDNF polymorphisms to suicidal behavior.
TrkB studies in suicide
Apart from BDNF, TrkB receptors have also been studied in 
relation to suicidal behavior. We examined the expression 
levels of TrkB in the same postmortem brain samples in 
which we determined the expression levels of BDNF. We 
found that the expression of full-length TrkB was significantly 
decreased in the PFC and hippocampus of suicide subjects 
compared with nonpsychiatric healthy controls. Interestingly, 
we did not find changes in expression of truncated isoform 
of TrkB (TrkB.T1). We found similar changes in PFC and 
hippocampus of teenaged suicide subjects.184 Our finding of 
decreased full-length TrkB expression in the suicide brain 
specimen may have serious implications. The decrease 
in full-length TrkB would not only affect BDNF-induced 
signaling but also the supply of BDNF to neurons and, thus, 
the loss of trophic maintenance of a variety of neuronal 
types, because the catalytically active full-length TrkB is 
present predominantly within neuronal axons, cell soma, 
and dendrites.195 In addition, the undiminished numbers of 
truncated TrkB would only exacerbate any effects as a result 
of the loss of catalytically active full-length TrkB, because 
truncated TrkB inhibits BDNF-mediated neurite outgrowth 
via the internalization of BDNF. More recently, we examined 
the functionality of full-length TrkB. We found that tyrosine 
phophorylation of TrkB was significantly compromised in 
the brain specimens of suicide subjects.196 These studies 
suggest that not only BDNF and TrkB are less expressed, 
but the functioning of TrkB is also impaired, in suicide brain 
specimens.
In a recent study, Ernst et al197 studied truncated TrkB 
(TrkB.T1) in frontal cortical regions and the cerebellum 
of suicide subjects. They found that about 36% of suicide 
completers had significant decreases in different probe sets 
specific to TrkB.T1 in frontal cortical areas but not the cer-
ebellum. The decrease in TrkB expression was specific to the 
T1 splice variant. There was no effect of genetic variation in 
a 2500-base pair promoter region or at relevant splice junc-
tions; however, an effect of methylation state at particular 
CpG dinucleotides on TrkB.T1 expression was noted. These 
results suggested a reduction in TrkB.T1 expression in 
suicide subjects, which was associated with the epigenetic 
modification of the TrkB.T1 promoter region.
p75NTr studies in suicide
p75NTR, initially discovered as a low-affinity receptor for 
NGF, is now known as a class of receptor that can bind to 
all neurotrophins with equivalent nanomolar affinities.198 
The 3.8-kb mRNA for p75NTR encodes a 427-amino acid 
protein containing a 28-amino acid single peptide, a single 
transmembrane domain, and a 55-amino acid cytoplasmic 
domain.199 Although p75NTR receptors do not contain a 
catalytic motif, they interact with several proteins, includ-
ing Trk receptors, which causes enhancement of ligand 
specificity and ligand affinities for Trk receptors.200–202 
Functionally, in contrast to Trk receptors, which contain 
autophosphorylation sites and are involved in cell survival, 
p75NTR lacks intrinsic enzymatic activity and can transmit 
both positive and negative signals.203 It has been shown that 
p75NTR can mediate neuronal apoptosis when the cognate Trk 
receptor is less activated or not activated.204 Similarly, p75NTR 
can cause developing hippocampal neuronal death induced 
by neurotrophins in the absence of a Trk receptor.205–207 In 
the adult CNS, it has been shown that excitotoxin-induced 
neuronal apoptosis is accompanied by the induction of p75NTR 
in the dying neurons,208 which suggests that p75NTR may 
represent a general stress-induced apoptotic mechanism.209 
However, the apoptotic mechanisms of p75NTR are active 
only when Trk receptors are less expressed or less active. 
Moreover, ectopic expression of the appropriate Trk receptor 
can convert a proapoptotic neurotrophin to a prosurvival 
neurotrophin. Thus, it appears that the ratio of expression 
levels and/or activation states of Trk receptors and p75NTR is 
quite relevant in neurotrophin-mediated functions. Recently, 
we observed that the expression ratio of p75NTR to Trk 
receptors is increased in the postmortem brain specimens of 
suicide subjects. Reduced expression of neurotrophins181,210 
together with reduced expression and activation of Trk and Neuropsychiatric Disease and Treatment 2009:5 443
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concomitant increased expression of p75NTR indicate that 
the possible consequence is a tipping of the balance away 
from cell survival, which could be associated with structural 
abnormalities and reduced neuronal plasticity in suicide 
brain specimens.
The two major signaling pathways activated by Trks are 
Ras-Raf extracellular signal–regulated kinase (ERK) and 
phosphoinositide 3-kinase (PI3-kinase)-Akt. In addition, phos-
pholipase Cγ binds to activated Trk receptors and initiates an 
intracellular signaling cascade that results in the activation of 
protein kinase C. On the other hand, p75NTR stimulates several 
proapoptotic pathways, which include C-Jun kinase signaling, 
sphingolipid turnover, and association with adaptor proteins, 
such as neurotrophin receptor–interacting MAGE homolog 
(NRAGE) and p75NTR-associated cell death executor (NADE), 
that directly promote cell cycle arrest and apoptosis.211–214 Trk 
receptors suppress the major proapoptotic signaling pathway, 
c-Jun kinase, initiated by p75NTR.215 In sympathetic neurons, 
Ras-mediated activation of PI3-kinase is required to sup-
press this signaling pathway.216 Activation of Trk receptors 
completely suppresses the activation by p75NTR of sphingomy-
elinase through the association of activated PI3-kinase with 
acidic sphingomyelinase.217,218 Sphingomyelinase activation 
results in generation of ceramide, which promotes apop-
tosis by inactivating ERK and PI3-kinase pathways.219–221 
Interestingly, we have reported less-activated ERK1/2222,223 
and PI-3 kinase224 in both the PFC and the hippocampus of 
suicide subjects. These findings could be associated with less 
activation/expression of Trks. These findings also indicate 
suboptimal activation of prosurvival pathways. Conversely, 
if p75NTR is more abundantly expressed, this may lead to 
proapoptotic signaling. Further studies are required to 
determine whether proapoptotic pathways are activated in 
the brain specimens of suicide subjects and how Trk- and 
p75NTR-mediated signal transduction pathways interplay in 
the pathophysiology of suicide.
Recently, it has been shown that pro-BDNF binds 
preferentially to p75NTR and elicits apoptosis as opposed 
to mature BDNF, which binds weakly with p75NTR but 
with high affinity to TrkB, where it exerts neuroprotective 
activity.60,225 Thus, pro-BDNF and mature BDNF cause 
opposite physiological actions through binding to p75NTR 
and TrkB receptors, respectively.55 In fact, it has been shown 
that pro-BDNF facilitates long-term depression via activation 
of p75NTR.226 On the other hand, TrkB plays a critical role 
in early-phase long-term potentiation227 and conversion of 
pro-BDNF to mature BDNF is essential for TrkB-mediated 
late-phase long-term potentiation.61 In a recent preliminary 
study, we observed that the level of pro-BDNF is increased 
PFC and hippocampus of suicide subjects (unpublished 
observation), whereas a recent genetic study suggests that 
the S205L polymorphism, which substitutes a serine with 
a leucine residue, of the p75NTR gene is associated with 
attempted suicide.228 These studies reveal the crucial roles 
of pro-BDNF and p75NTR in suicidal behavior.
Conclusion and future studies
Several preclinical and clinical observations indicate that 
depression may be associated with the inability of neural 
systems to exhibit adaptive plasticity. Given the role of 
BDNF and its cognate receptors in neural and structural 
plasticity, and that depression and antidepressants exert 
opposite actions on BDNF and TrkB expression and 
functions, it is apparent that BDNF signaling may be crucial 
in the pathophysiology of depression and in the mechanism 
of action of antidepressants. It is still unclear how a decrease 
in BDNF expression leads to depression. Genetic BDNF 
knock-in and knock-out models could possibly answer this 
question. However, recent studies suggest that a reduction 
in BDNF level in BDNF heterozygous knockout mice 
does not produce depression-like symptoms,229 although 
overexpression of TrkB reduces anxiety and depressive 
behavior in mice.230,231 On the other hand, overexpression 
of TrkB.T1 fails to induce a depression-like effect in the 
forced swim test.121 Thus, more in-depth studies are required 
to answer this question.
For suicidal behavior, the studies showing abnormalities in 
BDNF signaling in suicide are compelling. Many postmortem 
brain studies in patients who complete suicide and in those 
with suicidal ideation or attempted suicide show decreased 
BDNF expression and abnormalities in its cognate TrkB/
TrkB.T1 receptor. Although depression is an important factor 
in suicide, some studies were able to differentiate suicidal 
behavior vs depressive behavior in terms of decreased level 
of BDNF. Genetic studies also indicate an association of 
BDNF to suicidal behavior. Not only BDNF, but signaling 
mechanisms to which BDNF mediates its functions are also 
impaired in the brain specimens of suicide subjects. From 
these studies, it can be assumed that a decrease in BDNF 
in suicide subjects is independent of psychiatric illness and 
stress diathesis; however, further studies will be required to 
answer this complex question.
There are many avenues in BDNF research in depression/
suicide that need further attention. For example, what role 
does dendritic localization of BDNF/TrkB play in altered plas-
ticity in these disorders? What is the significance of enhanced Neuropsychiatric Disease and Treatment 2009:5 444
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expression of pro-BDNF and p75NTR in the development of 
depressive/suicidal behavior? Recently, it has been shown 
that BDNF and TrkB regulate translational machinery in 
dendrites.232 Moreover, BDNF induces the expression of 
Lim kinase 1, a protein kinase whose mRNA translation 
is inhibited by brain-specific microRNA-134. microRNA 
134 is localized in dendrites and its overexpression leads to 
a decrease in spine size through repression of Lim kinase 
1 mRNA translation.233 Thus, studying BDNF/TrkB and other 
interacting proteins in dendrites will further reveal their novel 
mechanistic roles in the development of depression/suicidal 
behavior.
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